Physician profile
Tammy Baker
NPI 1700260346
$11,887.82
in general payments reported to CMS, 2019-2025
41 companies · $3,722 in 2025
The $3,722 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,351 · 2022: $1,696 · 2023: $1,908 · 2024: $3,211 · 2025: $3,722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,823 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,823.25 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,374.85 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,963.86 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,332.60 | 2021-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $745.30 | 2021-2025 | Glassia |
| Insmed, INC. | $676.19 | 2023-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $557.31 | 2022-2025 | |
| Grifols USA, LLC | $556.99 | 2021-2025 | Prolastin-C Liquid, Xembify |
| Actelion Pharmaceuticals US, INC. | $531.05 | 2021-2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $459.09 | 2021-2025 | Ofev, Stiolto Respimat |
| United Therapeutics Corporation | $252.57 | 2021-2025 | Tyvaso, Tyvaso |
| Paratek Pharmaceuticals, INC. | $231.95 | 2021-2025 | Nuzyra |
| Verona Pharma, INC. | $210.00 | 2025 | Ohtuvayre |
| Janssen Pharmaceuticals, INC | $198.13 | 2021-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $197.13 | 2024-2025 | Winrevair |
| Jazz Pharmaceuticals INC. | $178.03 | 2021-2025 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $166.96 | 2021-2025 | Smartvest |
| Amgen INC. | $131.53 | 2022-2025 | Tezspire |
| Mylan Specialty L.P. | $126.89 | 2021-2024 | Yupelri |
| Inogen, INC. | $112.44 | 2023-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Novo Nordisk INC | $86.59 | 2024 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $83.04 | 2021 | |
| Viatris Specialty LLC | $82.26 | 2025 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $74.27 | 2021-2024 | |
| Atricure, INC. | $66.09 | 2023 | |
| Inspire Medical Systems, INC. | $60.15 | 2024 | Inspire |
| Ani Pharmaceuticals, INC. | $54.50 | 2025 | Purified Cortrophin Gel |
| Baxter Healthcare | $49.56 | 2023-2024 | Hillrom - Vest System Model 105 Home Care |
| Philips North America LLC | $39.52 | 2022-2023 | |
| Harmony Biosciences LLC | $30.80 | 2021-2023 | Wakix |
| Boston Scientific Corporation | $29.11 | 2023 | Watchman Access System |
| Impulse Dynamics (USA) INC. | $28.13 | 2024 | Optimizer |
| Janssen Biotech, INC. | $27.69 | 2025 | Tremfya |
| Lilly USA, LLC | $24.62 | 2025 | Zepbound |
| Shionogi INC | $24.11 | 2022 | |
| Nabriva Therapeutics, Plc | $21.49 | 2022 | |
| Tactile Systems Technology INC | $21.05 | 2024 | Entre Plus, Flexitouch Plus |
| Advanced Respiratory, INC | $19.13 | 2021 | |
| Sandoz INC. | $17.45 | 2022 | |
| Horizon Therapeutics Plc | $16.74 | 2023 | Krystexxa |
| Idorsia Pharmaceuticals US INC | $15.34 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $13.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.